

Cover Story
Regulatory News
In a 14:1 vote, ODAC nixes a PD-1 drug developed in China; data not generalizable to U.S. population
By Paul Goldberg and Alice Tracey
The FDA Oncologic Drugs Advisory Committee expressed decisive support for the agency’s view that data from trials of checkpoint inhibitors performed in mainland China aren’t applicable to the U.S. population.
White House
By Matthew Bin Han Ong
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74
- CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - In the 90s, Barry Kramer persuaded NCI to get out of the business of screening guidelines
At the time, USPSTF was better equipped to do the job. Is it still?
















